In a U.S. cohort of 157,333 people living with hepatitis B, only 6.7% had ever been tested for hepatitis D, according to the Centers for Disease Control and Prevention. A separate review of Veterans Affairs records put the figure at 19.7%.
Hepatitis D, also called hepatitis delta, needs hepatitis B to survive, so it appears only in people already living with that infection. A hepatitis B diagnosis should prompt a hepatitis D test, and that second test is often skipped. The gap reaches back to the people developing new treatments, including biotechnology executive and investor Leen Kawas, whose work focuses on patients with serious unmet medical needs. A therapy can’t help a patient who has never been tested and connected to care.
Why Hepatitis D Deserves Greater Attention
The hepatitis D virus cannot replicate on its own. It needs hepatitis B, so infection happens either at the same time as a new hepatitis B infection or later, in someone who already has chronic hepatitis B. The California Department of Public Health notes that the second pattern, called superinfection, can lead to cirrhosis, liver cancer, end-stage liver disease and death.
In 2025, the World Health Organization’s cancer research agency classified hepatitis D as carcinogenic to humans. WHO puts its liver cancer risk at two to six times that of hepatitis B alone.
Its symptoms look the same as those of hepatitis B, so a clinician who doesn’t test for it specifically can mistake a hepatitis D infection for hepatitis B that is getting worse.
Testing for Hepatitis B and Hepatitis D Are Separate Steps
In 2023, the CDC began recommending that every adult 18 and older be screened for hepatitis B at least once, using a three-test panel that looks for hepatitis B surface antigen, surface antibody and core antibody, as summarized by the University of Washington’s Hepatitis B Online. A positive surface antigen result means a current hepatitis B infection.
That panel does not detect hepatitis D. Finding it takes two more tests. The first is a total antibody test for hepatitis D, which shows whether a person has ever been exposed. A positive result is then followed by an HDV RNA test, which confirms whether the virus is actively replicating. The CDC’s surveillance criteria treat the antibody as presumptive evidence and the RNA test as confirmation.
In a 2024 Quest Diagnostics analysis cited by the CDC, 1.6% of 2,646 hepatitis B surface antigen-positive samples had hepatitis D antibodies, and 39% of those showed active infection on RNA testing. Without the RNA step, a clinician couldn’t tell which of those patients were still infected.
WHO’s 2024 hepatitis B guidelines recommend offering the antibody test to everyone who tests positive for hepatitis B surface antigen. They also favor reflex testing, in which the lab runs the antibody test automatically after a positive hepatitis B result, then the RNA test after a positive antibody result.
The Challenge of Finding Undiagnosed Patients
Only 13% of people living with hepatitis B worldwide had been diagnosed by 2022, according to WHO. Each undiagnosed case is also a hepatitis D test that will never be ordered.
In the United States, the CDC says the true burden of hepatitis D is unknown because testing and reporting practices are limited and inconsistent. At a large Central European hospital, researchers found that 98.0% of hepatitis B patients were screened for hepatitis D antibodies when testing ran automatically, compared with 65.1% when clinicians had to order it by hand.
WHO has described hepatitis D as a disease that often affects underserved and vulnerable groups, including people who inject drugs and people living with HIV or hepatitis C. Many of them have limited contact with routine care, so reaching them depends on testing that happens at the first visit.
Why Early Detection Matters for Patients
A confirmed diagnosis gives clinicians a reason to refer the patient to a liver specialist and to watch closely for cirrhosis and liver failure, which hepatitis D can accelerate, according to the CDC. Patients with both infections also need different treatment plans than those with hepatitis B alone, the Hepatitis B Foundation advises, and some may be candidates for clinical trials. WHO describes the treatment options for hepatitis D as still evolving.
A diagnosis also prompts hepatitis B testing for household members and vaccination for anyone not yet protected. The hepatitis B vaccine prevents hepatitis D as well, since the second virus can’t take hold without the first.
None of it happens unless patients come back. They need to understand what a hepatitis D result means and why follow-up testing is worth the return visit.
Leen Kawas and the Full Patient Journey
Kawas has spent her career in drug development as a scientist, executive and investor, and that work has shown her how much of a patient’s outcome is decided before treatment begins.
For hepatitis D, the path to care runs through awareness, a hepatitis B screen, two follow-up tests and a referral that actually happens. A break at any point leaves the patient outside the system, no matter how good the available treatment is.
Kawas’s emphasis on patient-centered healthcare treats each of those steps as part of the work, with diagnosis carrying as much weight as discovery.
Closing the Testing Gap
Hepatitis D awareness lags well behind the severity of the disease, and U.S. testing rates as low as 6.7% show how many patients slip through. Wider awareness among clinicians and patients, combined with consistent testing after every positive hepatitis B result, would connect more of them to care.
Kawas judges healthcare innovation by whether it reaches patients and improves their lives. For hepatitis D, reaching them starts with a test.
